Human Hallucinogenic Drug Research: Regulatory, Clinical, and Scientific Issues

Rj, Strassman

doi:10.1037/e495832006-007

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These cases typically resolve spontaneously with supportive care. 17 There are reports of prolonged psychiatric symptoms after LSD use, but this response remains rare. In one survey of 5000 people to whom LSD or mescaline had been administered in therapeutic and research settings, adverse psychiatric reactions lasting more than 48 hours, including psychosis, were reported in 0.08 per cent of research volunteers and 0.18 per cent of psychiatric patients.…”

Section: Safety Profile Of the Psychedelic Drugs When Used Clinicallymentioning

confidence: 99%

Are psychedelic drug treatments seeing a comeback in psychiatry?

Sessa¹

2008

Prog Neurol Psychiatry

View full text Add to dashboard Cite

After a hiatus of nearly 40 years, psychedelic drugs (or hallucinogens) are being increasingly researched as possible adjuncts to psychotherapy for treatment-resistant anxiety disorders and addictions.This research offers an exciting future for this class of drugs whose image has been tarnished by recreational use since the 1960s.Through cautious and evidence-based studies, these medications could be finding their way back to where they began their lives: as valid and effective tools for clinical medicine and neuroscientific research.

show abstract